News

Lucy Foulston and Professor Mervyn Bibb.

Key milestone towards the development of a new clinically useful antibiotic
July 2010
Scientists from the John Innes Centre have identified the genes necessary for making a highly potent and clinically unexploited antibiotic in the fight against multi-resistant pathogens.

"Lantibiotics are antibiotic molecules produced by soil bacteria, and we are studying probably the most potent one known, microbisporicin, which is active against many different pathogens," said Professor Mervyn Bibb from the John Innes Centre, co-author on the paper to be published in PNAS.

The producing bacterium, Microbispora corallina, is difficult to work with. It grows very slowly and no tools existed for its genetic manipulation. PhD student Lucy Foulston developed the tools herself. She then took advantage of new developments in genome sequencing to identify and then isolate the M. corallina gene cluster responsible for microbisporicin production.

Streptomyces coelicolor developmental mutant.

Lifeline for antibiotic of last resort
July 2010
An international team of scientists has uncovered how bacteria sense vancomycin, a mechanism that triggers resistance to this powerful antibiotic.

"Vancomycin resistance is thankfully still rare in MRSA, but if it became more widespread we could risk edging backwards to the pre-antibiotic era," says Professor Mark Buttner from the John Innes Centre, an institute of BBSRC. "We need to have a back-up ready in case resistance becomes more common."

'A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor' was published online in Nature Chemical Biology, 11 April 2010, doi 10.1038/NCHEMBIO.350

A mutant deficient in lipoprotein biogenesis.

Spitting out detergents and chewing up pollutants
July 2010
A team of scientists from UEA and Dundee have discovered a novel way in which Streptomyces bacteria export and display proteins on their cell surface. Led by Dr Matt Hutchings (UEA) in collaboration with Professor Tracy Palmer (Dundee) the team have exploited this natural pathway to develop strains of Streptomyces and Bacillus bacteria that can secrete or cell surface display proteins that could be useful for industry or medicine. This technology has been patented by UEA and licensed exclusively to PBL.

The research is described in a paper published in the journal Molecular Microbiology (doi 10.1111/j.1365-2958.2010.07261.x). The team anticipate that this technology will be widely applicable for industrial and biomedical use, for example to produce enzymes for biological washing powders or antibodies for therapeutic use. The work was funded by research grants from the BBSRC and technology development grants from the BBSRC and UEA.

Sainsbury Laboratory

GM Trial to reduce agrochemicals
June 2010
A field trial of GM potatoes is being planted this week to test whether genes from wild relatives can successfully protect commercial potato varieties from late blight – the disease that caused the Irish potato famine – without the need to spray fungicides.

At the moment British farmers spray on average 15 times a year to protect against potato late blight.

"We have isolated genes from two different wild potato species that confer blight resistance," said Professor Jonathan Jones from the Sainsbury Laboratory on Norwich Research Park. "Similar genes are found in all plants, and we are now testing whether these ones work in a field environment to protect a commercial potato variety, Desiree, against this destructive potato disease."

John Innes Centre

What is the JI's most significant contribution?
May 2010
The John Innes Centre and the Sainsbury Laboratory were recently ranked number one of the world's "top institutions in plant and animal sciences." But now the John Innes Centre wants you to vote on what you think is the most important contribution it has made to plant and microbial science over the last 100 years.

One of the five research areas, which Prof. Mervyn Bibb is supporting and can be voted for, is Antibiotic Research. The most significant contribution being JIC pioneered the genome sequencing of Streptomyces.

The winner will be announced in July as JIC brings its centenary celebrations to a close.
So vote now!

JI 100

Forward Look Conference - 14th July 2010
May 2010
The John Innes Centenary year will close with a forward look conference in July 2010, which will take place at The Royal Institution, Faraday Theatre, London; where researchers will look 100 years on and discuss what they think the grand challenges of the future will be.

Appearing will be:

Click here for the full programme

campylobacter jejuni

Biofilm production aids campylobacter survival
March 2010
Scientists at the Institute of Food Research have found a way that the foodborne pathogen Campylobacter can survive in the environment. Campylobacter is the main cause of food poisoning in Europe and America.

Campylobacter cannot survive in the oxygen levels in the air, which forces the bacterium to adapt for survival in the food chain. One such a survival strategy is to form a biofilm, whereby the bacteria stick to a surface and encase themselves in a sticky 'slime' which protects them.

"While biofilms are well established in the lifestyle and success of other pathogenic bacteria, their role in the lifestyle of Campylobacter was still unclear. We now have developed a model where the biofilm plays a central role in the transmission of Campylobacter via the food chain, and this may lead to new antimicrobial approaches, like disrupting the biofilm matrix or prevention of biofilm formation." commented Dr. Arnoud van Vliet.

Mycobacterium tuberculosis

Scientists make TB bug suicidal
March 2010
Dr Steph Bornemann and scientists from the Albert Einstein College of Medicine of Yeshiva University (Einstein), in New York, have identified a new class of drug target that tricks tuberculosis bacteria into suicidal self-poisoning. Researchers identified the role that an enzyme called GlgE plays in Mycobacterium tuberculosis, the cause of tuberculosis and the leading cause of death worldwide from bacterial pathogens. It claims about two million lives every year.

"With the advent of antibiotics, TB became treatable and at one point eradication was believed possible," says Dr Steph Bornemann from the John Innes Centre.

"But TB has re-emerged as a major global health threat due to poverty, a deadly synergy with HIV and the emergence of drug resistant strains that are virtually untreatable with current therapies."

Together the scientists have identified a four-step metabolic pathway involving GlgE that represents a new target for anti-tuberculosis drugs.

tomato plants infected with Ralstonia solanacearum

New defences deployed against plant diseases
March 2010
An international team led by scientists at the Sainsbury Laboratory in Norwich have transferred broad spectrum resistance against some important plant diseases across different plant families. This breakthrough provides a new way to produce crops with sustainable resistance to economically important diseases.

Plants have a defence system, based on pattern recognition receptors (PRRs). PRRs recognise molecules that are essential for pathogen survival. These molecules are less likely to mutate without harming the pathogen’s survival, making resistance to them more durable in the field. However, very few of these PRRs have been identified to date. Dr Cyril Zipfel and his group at the Sainsbury Laboratory in Norwich, UK, took a Brassica-specific PRR that recognises bacteria, and transformed it into the Solanaceae plants Nicotania benthaminia and tomato. These plants then showed drastically enhanced resistance against many different bacteria indicating that this approach provides a new biotechnological solution to engineering disease resistance in plants.

Dr Michael McArthur

JIC scientist wins prestigious national award
March 2010
Dr Michael McArthur has been named the winner of 'Most Promising Innovator of the Year' award for his work using novel antibacterials to combat drug-resistant bacterial infections. Dr McArthur has developed novel technologies to combat drug resistant bacterial infections, such as MRSA and a spin-out company from the John Innes Centre, Procarta Biosystems, is now taking this technology through to the marketplace.

"Over the last decade all the major pharmaceutical companies have been bringing fewer antibiotics to the market, some have even departed the field altogether, a trend that is likely to be exacerbated by resistance issues. Procarta's novel solution not only tackles antibiotic resistance but also is a solution which should be far less susceptible to resistance" said Michael.

Sarum Biosciences

Clostridium difficile bacteriophage endolysin technology
January 2010
Sarum Biosciences Limited ("Sarum") and PBL, the UK technology management company, announced on 22nd February the signing of an exclusive worldwide licence agreement which enables Sarum to develop and exploit therapeutic and diagnostic applications of a bacteriophage endolysin protein for the treatment and detection of Clostridium difficile, a serious healthcare concern both within the UK and the rest of the world.

"Using bacterial endolysins has been of interest to IFR for many years in the food context," said Dr Arjan Narbad of the IFR, an institute of the BBSRC, which funded the study. "Now we have an endolysin that is active specifically against C. difficile we are looking forward to developing it into a potent weapon against this problem."

Go to News Archive

Institute of Food ResearchJohn Innes CentreSainsbury LabUniversity of East Anglia